[197+ Pages Report] Over the projected period, the adult hemoglobinopathy testing market is projected to develop rapidly. The global adult hemoglobinopathy testing market was worth USD 330 Million in 2020 and is expected to be worth about USD 430 Million by 2026, expanding at a CAGR of 3.9%.
Hemoglobinopathy is caused by genetic abnormalities and anemia. Structure defects in the hemoglobin molecule decreased synthesis of one of the two subunits of the hemoglobin molecule, and pathological interactions of normally usual subunits both contribute to the development of irregular hemoglobin. There are two types of disorders: extreme and moderate. The hemoglobin (Hb) molecule is either decreased in development or has its structure altered as a result of these mutations. The existence of variant hemoglobin in red blood cells causes hemoglobinopathy disease. The global adult hemoglobinopathy testing market is expected to grow at a rapid pace as a result of a number of government-provided health services, such as payment programs for therapies and diagnostic tests, as well as the care of current hemoglobinopathy patients. NGO's are now working hard to develop advanced research techniques for hemoglobinopathy diagnosis. Global adult hemoglobinopathy is also on the rise due to factors such as NGO and government cooperation to create more innovative diagnostic methods, the rapid expansion of POC diagnosis methods, and low-cost therapies.
The adult hemoglobinopathy testing market is anticipated to rise over the forecast period owing to increasing incidences of sickle cell disease, thalassemia, and other hemoglobinopathies. The industry is also influenced by policymakers' increasing support for measuring and controlling diseases related to blood, as well as advances in technology. During the forecast period, the developing region is expected to provide growth opportunities for the industry. The global adult hemoglobinopathy testing market is expected to face some challenges that could limit its expansion. Adult hemoglobinopathy research market development is likely to be hampered by a lack of knowledge about hemoglobinopathy disorders and testing in various developing and underdeveloped emerging economies. The market's development may be hampered by a lack of innovative screening technology procedures such as genetic testing, the sophistication of hemoglobinopathy tests, and the disease's rising prevalence.
COVID-19 began in December of 2019 in Wuhan, China, and has quickly spread around the world since then. Given the rapid spread of the pandemic and the shortage of research, proper treatment and management of Coronavirus (COVID-19) infection in patients affected by adult Hematological testing could be difficult, particularly in some countries. Various programs are putting forward attempts at this critical point to generate papers with indications for the health treatment of these patients. Adult hemoglobinopathy research firms should take care of this opportunity. COVID-19 has also unleashed a slew of new opportunities for several private firms to join the market in order to satisfy the significant challenge. Apart from that, a programme that calculates hemoglobinopathy testings automatically is gaining popularity as an alternative to traditional studies. In addition, owing to the widespread outbreak of coronavirus disease (COVID-19) and the absence of an appropriate vaccine or cure, Adult hemoglobinopathy testing research is being used to measure the effectiveness of existing medications as a potential treatment, which is boosting market development. The expansion of the Adult hemoglobinopathy testing research industry has been aided by the COVID-19 pandemic. It's used to find potential COVID-19 drug candidates and to assess the cell model using Adult hemoglobinopathy testing. As a result, demand for Adult hemoglobinopathy testing research is projected to increase in 2020, boosting market share.
The global adult hemoglobinopathy testing market is bifurcated into its Variant Type, Test Type, distribution channel, and regions. Based on the variant type, the global market is divided into Variant A2, and Variant F. Based on Test Type, the market is bifurcated into HPLC test, mass spectrometry, and hemoglobin electrophoresis. Based on the End User, the market is segmented into reference laboratories, hospitals, and academic & medical institutes. Geographically, the global adult hemoglobinopathy testing market is diversified into North America, Asia-Pacific, Europe, Middle East & Africa, and Latin America.
The global adult hemoglobinopathy testing market is dominated by Europe, which is predicted to continue to do so over the forecast period. Because of the increasing prevalence of hemoglobinopathy in countries like India and China, Asia Pacific is projected to rise faster than the rest of the world during the forecast period. Sickle Cell Anemia is a global health problem that is most prevalent in African and Sub-Asian countries, according to the World Health Organization. A significant number of people from the affected areas are migrating to Europe and North America, resulting in an increase in the number of new cases of hemoglobinopathy disorders being diagnosed. The adult hemoglobinopathy testing market is expected to boom in northern and central Europe, especially Germany, as a result of increased migration. Similarly, as a result of increased migration from Asia, the number of hemoglobinopathy cases observed in North America has increased, fueling the hemoglobinopathy testing market over the projected era. In the face of rising hemoglobinopathy genotypes, policymakers have implemented a variety of public health initiatives, such as genetic testing, screening services, and counseling, which will continue to propel the global adult hemoglobinopathy testing market within the forecast period.
Some of the key players in the adult hemoglobinopathy testing market are Chromsystems Instruments & Chemicals GmbH, PerkinElmer Inc., CapitalBio Technology Inc., Bio-Rad Laboratories, Inc., BioMedomics, Inc., Streck, Inc., Thermo Fisher Scientific Inc., Trinity Biotech, Baxter, and Bluebird Bio among others.
Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.
Still haven't found what you're looking for? Speak to our Custom Research TeamLearn More